• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Novelos Therapeutics

edit

Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company focused on developing and commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. The Company’s compound, NOV-002 is a small-molecule compound based on a formulation of oxidized glutathione that has been administered to approximately 1,000 cancer patients in clinical trials. As of December 31, 2009, NOV-002 was in Phase II development for solid tumors in combination with chemotherapy. The Company’s second glutathione-based compound, NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties.

Recent Milestones

edit

• 
  Novelos Therapeutics — Novelos closes $5M offering; fraud complaint dismissed (6/14/12)
  Posted 6/14/12 at 5:24pm via masshightech.com
• 
  Novelos Therapeutics received $5.1M in Venture Round funding. (4/11/11)
  Posted 4/11/11 at 7:57pm via novelos.com
• 
  Novelos Therapeutics acquired Cellectar. (4/11/11)
  Posted 4/11/11 at 7:53pm via novelos.com
• 
  Novelos Therapeutics added Harry S. Palmin as President & CEO.
  Posted 4/11/11 at 7:44pm

Videos

Screenshots

edit

Sources

1. NOVELOS THERAPEUTICS COMPLETES ACQUISITION AND $5.1 MILLION FINANCING TO DEVELOP 3 NOVEL CANCER-TARGETED COMPOUNDS (novelos.com) [edit]
2. NOVELOS THERAPEUTICS COMPLETES ACQUISITION AND $5.1 MILLION FINANCING TO DEVELOP 3 NOVEL CANCER-TARGETED COMPOUNDS (novelos.com) [edit]
Novelos closes $5M offering; fraud complaint dismissed (masshightech.com) [edit]